FDA Approves Label Expansion for VENTANA MMR RxDx Panel

On August 11, 2022, the U.S Food and Drug Administration (FDA)  approved a label expansion for the VENTANA MMR RxDx Panel, a companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA mismatch repair, and who may be eligible for treatment with Keytruda^®(pembrolizumab).

For more information read the Roche announcement.  

Posted on 8/11/2022